Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

The crystal structure of the protein kinase HIPK2 reveals a unique architecture of its CMGC-insert region.

Agnew C, Liu L, Liu S, Xu W, You L, Yeung W, Kannan N, Jablons D, Jura N.

J Biol Chem. 2019 Sep 13;294(37):13545-13559. doi: 10.1074/jbc.RA119.009725. Epub 2019 Jul 24.

2.

PEAK3/C19orf35 pseudokinase, a new NFK3 kinase family member, inhibits CrkII through dimerization.

Lopez ML, Lo M, Kung JE, Dudkiewicz M, Jang GM, Von Dollen J, Johnson JR, Krogan NJ, Pawłowski K, Jura N.

Proc Natl Acad Sci U S A. 2019 Jul 30;116(31):15495-15504. doi: 10.1073/pnas.1906360116. Epub 2019 Jul 16.

PMID:
31311869
3.

More than the sum of the parts: Toward full-length receptor tyrosine kinase structures.

Diwanji D, Thaker T, Jura N.

IUBMB Life. 2019 Jun;71(6):706-720. doi: 10.1002/iub.2060. Epub 2019 May 2. Review.

PMID:
31046201
4.

Prospects for pharmacological targeting of pseudokinases.

Kung JE, Jura N.

Nat Rev Drug Discov. 2019 Jul;18(7):501-526. doi: 10.1038/s41573-019-0018-3. Review.

PMID:
30850748
5.

Functional role of PGAM5 multimeric assemblies and their polymerization into filaments.

Ruiz K, Thaker TM, Agnew C, Miller-Vedam L, Trenker R, Herrera C, Ingaramo M, Toso D, Frost A, Jura N.

Nat Commun. 2019 Jan 31;10(1):531. doi: 10.1038/s41467-019-08393-w.

6.

The pseudokinase TRIB1 toggles an intramolecular switch to regulate COP1 nuclear export.

Kung JE, Jura N.

EMBO J. 2019 Feb 15;38(4). pii: e99708. doi: 10.15252/embj.201899708. Epub 2019 Jan 28.

PMID:
30692133
7.

Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations.

Pahuja KB, Nguyen TT, Jaiswal BS, Prabhash K, Thaker TM, Senger K, Chaudhuri S, Kljavin NM, Antony A, Phalke S, Kumar P, Mravic M, Stawiski EW, Vargas D, Durinck S, Gupta R, Khanna-Gupta A, Trabucco SE, Sokol ES, Hartmaier RJ, Singh A, Chougule A, Trivedi V, Dutt A, Patil V, Joshi A, Noronha V, Ziai J, Banavali SD, Ramprasad V, DeGrado WF, Bueno R, Jura N, Seshagiri S.

Cancer Cell. 2018 Nov 12;34(5):792-806.e5. doi: 10.1016/j.ccell.2018.09.010. Epub 2018 Oct 25.

PMID:
30449325
8.

Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation.

Frazier NM, Brand T, Gordan JD, Grandis J, Jura N.

Oncogene. 2019 Mar;38(11):1936-1950. doi: 10.1038/s41388-018-0537-0. Epub 2018 Nov 2.

9.

Activating HER3 mutations in breast cancer.

Mishra R, Alanazi S, Yuan L, Solomon T, Thaker TM, Jura N, Garrett JT.

Oncotarget. 2018 Jun 12;9(45):27773-27788. doi: 10.18632/oncotarget.25576. eCollection 2018 Jun 12.

10.

Phosphorylated EGFR Dimers Are Not Sufficient to Activate Ras.

Liang SI, van Lengerich B, Eichel K, Cha M, Patterson DM, Yoon TY, von Zastrow M, Jura N, Gartner ZJ.

Cell Rep. 2018 Mar 6;22(10):2593-2600. doi: 10.1016/j.celrep.2018.02.031.

11.

Regulation of Kinase Activity in the Caenorhabditis elegans EGF Receptor, LET-23.

Liu L, Thaker TM, Freed DM, Frazier N, Malhotra K, Lemmon MA, Jura N.

Structure. 2018 Feb 6;26(2):270-281.e4. doi: 10.1016/j.str.2017.12.012. Epub 2018 Jan 18.

12.

Feedback regulation of RTK signaling in development.

Neben CL, Lo M, Jura N, Klein OD.

Dev Biol. 2019 Mar 1;447(1):71-89. doi: 10.1016/j.ydbio.2017.10.017. Epub 2017 Oct 26. Review.

PMID:
29079424
13.

Switching on BTK-One Domain at a Time.

Agnew C, Jura N.

Structure. 2017 Oct 3;25(10):1469-1470. doi: 10.1016/j.str.2017.09.012. Epub 2017 Oct 3.

14.

Retraction Notice to: An ATP-Competitive Inhibitor Modulates the Allosteric Function of the HER3 Pseudokinase.

Littlefield P, Moasser MM, Jura N.

Cell Chem Biol. 2017 Jul 20;24(7):917. doi: 10.1016/j.chembiol.2017.07.008. No abstract available.

15.

EGF and NRG induce phosphorylation of HER3/ERBB3 by EGFR using distinct oligomeric mechanisms.

van Lengerich B, Agnew C, Puchner EM, Huang B, Jura N.

Proc Natl Acad Sci U S A. 2017 Apr 4;114(14):E2836-E2845. doi: 10.1073/pnas.1617994114. Epub 2017 Mar 20.

16.

Structural Basis for the Non-catalytic Functions of Protein Kinases.

Kung JE, Jura N.

Structure. 2016 Jan 5;24(1):7-24. doi: 10.1016/j.str.2015.10.020. Review.

17.

Src defines a new pool of EGFR substrates.

Michael N, Jura N.

Nat Struct Mol Biol. 2015 Dec;22(12):945-7. doi: 10.1038/nsmb.3137. No abstract available.

PMID:
26643845
18.

Analysis of the Role of the C-Terminal Tail in the Regulation of the Epidermal Growth Factor Receptor.

Kovacs E, Das R, Wang Q, Collier TS, Cantor A, Huang Y, Wong K, Mirza A, Barros T, Grob P, Jura N, Bose R, Kuriyan J.

Mol Cell Biol. 2015 Sep 1;35(17):3083-102. doi: 10.1128/MCB.00248-15. Epub 2015 Jun 29.

19.

Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations.

Littlefield P, Liu L, Mysore V, Shan Y, Shaw DE, Jura N.

Sci Signal. 2014 Dec 2;7(354):ra114. doi: 10.1126/scisignal.2005786.

20.

RETRACTED: An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase.

Littlefield P, Moasser MM, Jura N.

Chem Biol. 2014 Apr 24;21(4):453-458. doi: 10.1016/j.chembiol.2014.02.011. Epub 2014 Mar 20. Retraction in: Cell Chem Biol. 2017 Jul 20;24(7):917.

21.

EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma.

Fan QW, Cheng CK, Gustafson WC, Charron E, Zipper P, Wong RA, Chen J, Lau J, Knobbe-Thomsen C, Weller M, Jura N, Reifenberger G, Shokat KM, Weiss WA.

Cancer Cell. 2013 Oct 14;24(4):438-49. doi: 10.1016/j.ccr.2013.09.004.

22.

A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties.

Murphy JM, Zhang Q, Young SN, Reese ML, Bailey FP, Eyers PA, Ungureanu D, Hammaren H, Silvennoinen O, Varghese LN, Chen K, Tripaydonis A, Jura N, Fukuda K, Qin J, Nimchuk Z, Mudgett MB, Elowe S, Gee CL, Liu L, Daly RJ, Manning G, Babon JJ, Lucet IS.

Biochem J. 2014 Jan 15;457(2):323-34. doi: 10.1042/BJ20131174.

23.

EGFR lung cancer mutants get specialized.

Littlefield P, Jura N.

Proc Natl Acad Sci U S A. 2013 Sep 17;110(38):15169-70. doi: 10.1073/pnas.1314719110. Epub 2013 Sep 10. No abstract available.

24.

Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms.

Jura N, Zhang X, Endres NF, Seeliger MA, Schindler T, Kuriyan J.

Mol Cell. 2011 Apr 8;42(1):9-22. doi: 10.1016/j.molcel.2011.03.004. Review.

25.

Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3.

Jura N, Shan Y, Cao X, Shaw DE, Kuriyan J.

Proc Natl Acad Sci U S A. 2009 Dec 22;106(51):21608-13. doi: 10.1073/pnas.0912101106. Epub 2009 Dec 9.

26.

Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment.

Jura N, Endres NF, Engel K, Deindl S, Das R, Lamers MH, Wemmer DE, Zhang X, Kuriyan J.

Cell. 2009 Jun 26;137(7):1293-307. doi: 10.1016/j.cell.2009.04.025. Erratum in: Cell. 2009 Aug 7;138(3):604.

27.

Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface.

Zhang X, Pickin KA, Bose R, Jura N, Cole PA, Kuriyan J.

Nature. 2007 Nov 29;450(7170):741-4.

28.

Mapping cellular routes of Ras: a ubiquitin trail.

Jura N, Bar-Sagi D.

Cell Cycle. 2006 Dec;5(23):2744-7. Epub 2006 Dec 1.

PMID:
17172849
29.

A mouse model of hereditary pancreatitis generated by transgenic expression of R122H trypsinogen.

Archer H, Jura N, Keller J, Jacobson M, Bar-Sagi D.

Gastroenterology. 2006 Dec;131(6):1844-55. Epub 2006 Oct 1.

PMID:
17087933
30.

Differential modification of Ras proteins by ubiquitination.

Jura N, Scotto-Lavino E, Sobczyk A, Bar-Sagi D.

Mol Cell. 2006 Mar 3;21(5):679-87.

31.

Inactivation of membrane tumor necrosis factor alpha by gingipains from Porphyromonas gingivalis.

Mezyk-Kopec R, Bzowska M, Potempa J, Bzowska M, Jura N, Sroka A, Black RA, Bereta J.

Infect Immun. 2005 Mar;73(3):1506-14.

32.

An ex vivo model for functional studies of myofibroblasts.

Kilarski WW, Jura N, Gerwins P.

Lab Invest. 2005 May;85(5):643-54.

33.

Chronic pancreatitis, pancreatic adenocarcinoma and the black box in-between.

Jura N, Archer H, Bar-Sagi D.

Cell Res. 2005 Jan;15(1):72-7. Review.

34.

Tumour necrosis factor-alpha stimulates expression of TNF-alpha converting enzyme in endothelial cells.

Bzowska M, Jura N, Lassak A, Black RA, Bereta J.

Eur J Biochem. 2004 Jul;271(13):2808-20.

35.
36.

hSpry2 is targeted to the ubiquitin-dependent proteasome pathway by c-Cbl.

Hall AB, Jura N, DaSilva J, Jang YJ, Gong D, Bar-Sagi D.

Curr Biol. 2003 Feb 18;13(4):308-14.

37.

Nasal airway volumetric measurement using segmented HRCT images and acoustic rhinometry.

Dastidar P, Numminen J, Heinonen T, Ryymin P, Rautiainen M, Laasonen E.

Am J Rhinol. 1999 Mar-Apr;13(2):97-103. Erratum in: Am J Rhinol 1999 Jul-Aug;13(4):334. Prasun, D [corrected to Dastidar, P]; Jura, N [corrected to Numminen, J]; Tomi, H [corrected to Heinonen, T]; Pertti, R [corrected to Ryymin, P]; Markus, R [corrected to Rautiainen, M]; Erkki, L [corrected to Laasonen, E].

PMID:
10219437

Supplemental Content

Support Center